Cipla Ltd

Stage 3 · Topping · week 9

As of 20 Nov 2026, Cipla is in Stage 3, the topping phase, now in week 9 (since 17 Sep 2026). It closed at ₹1,415, 7.9% below its 52-week high and above its 200-day average, which is falling. In Health Care, 34.7% of stocks are in Stage 2.

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. More about the company

₹1,415
Close, 20 Nov 2026
-0.25% on the day
₹1.14L Cr · Large cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

RS rank

Edge

—

CIPLA's uptrend is tiring: about 2 months into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.

Its relative strength is 57 of 99, above the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Is CIPLA early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 20w
S2 20w
S4 16w
S2 19w
S4 19w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 10w → S3 7w → S2 20w → S3 5w → S2 20w → S3 7w → S4 16w → S1 11w → S2 1w → S1 1w → S2 19w → S3 7w → S4 19w → S1 9w → S2 8w → S3 9w current
Total tracked: 169 weeks across 16 stage runs.

CIPLA among Pharmaceuticals76th of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…76CIPLAStage 3 · wk 957+7.7%
vs 52W High
-7.9%
₹1,192.4 lo₹1,535.6 hi
7.9% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 9
1w13w26w
Week 9, distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
3.6%
200 DMA: ₹1,365.5 · sloping down
The stock still holds above its 200-day average, but the trend has flattened. A close below the line would add to the Stage 4 risk.
Rel Volume
1.23x
vs 50-day avg
Volume was close to average, nothing unusual. In Stage 3, volume spikes on down days are the warning to watch for.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+7.7%
3M
-0.5%
6M
+1.1%
YTD
-6.4%
1Y
-7.3%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Industry has 48 Stage 2 leaders. See Pharmaceuticals Stage 2 →

Mutual fund holdings

Held by 189 mutual funds in portfolios to October 2026: 100 active funds and 89 index funds and ETFs.

In October, among active funds: 22 increased, 3 opened a new position, 11 reduced and 4 exited.

25 increased or opened15 reduced or exited
All 189 funds, the 4 that exited, and what each did in October

Mutual funds holding CIPLA: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 22 Jul 2026
Recent Stage Timeline
2026-11-20S3
Wk 9 · Vol 1.23x
2026-11-19S3
Wk 9 · Vol 1.67x
2026-11-18S3
Wk 9 · Vol 2.53x
2026-11-17S3
Wk 9 · Vol 0.89x
2026-11-16S3
Wk 8 · Vol 1.10x
2026-11-13S3
Wk 8 · Vol 0.90x
2026-11-12S3
Wk 8 · Vol 1.52x
2026-11-11S3
Wk 8 · Vol 1.59x
2026-11-09S3
Wk 8 · Vol 1.60x
2026-11-06S3
Wk 7 · Vol 1.49x
2026-11-05S3
Wk 7 · Vol 1.17x
2026-11-04S3
Wk 7 · Vol 1.27x
Moving averages & range
50 DMA
₹1,367.1
200 DMA
₹1,365.5
52W High
₹1,535.6
52W Low
₹1,192.4
5D Low
₹1,388
Resistance levels (recent highs)
20d High
₹1,419.9
60d High
₹1,423.5
120d High
₹1,477
250d High
₹1,531.3
Next resistance
+0.3%
to 20d High
P/E (TTM)
38.8
Forward 22.3
Earnings Growth (YoY)
-35.0%
Revenue -1.1%
ROE
+8.3%
Profit margin +10.4%
Dividend Yield
0.93%
P/B 3.2

Cipla: quick answers

What stage is Cipla in?

As of 20 Nov 2026, Cipla (CIPLA) is in Stage 3, the topping phase. It entered Stage 3 on 17 Sep 2026 and is in week 9. What the four stages mean

Is Cipla in an uptrend?

Its uptrend has stalled. Cipla is in Stage 3, the topping phase that follows an advance. It trades 3.6% above its 200-day average, which is falling.

How far is Cipla from its 52-week high?

Cipla closed at ₹1,415 on 20 Nov 2026, 7.9% below its 52-week high of ₹1,536. Its 52-week low is ₹1,192.

How has Cipla performed over the past year?

As of 20 Nov 2026, Cipla is down 7.3% over the past year and down 6.4% so far in 2026.

Is Cipla in F&O, and what is its lot size?

Yes. Cipla (CIPLA) trades in NSE's F&O segment, with a near-month lot size of 425 shares as of 20 Nov 2026. NSE revises lot sizes a few times a year; ours are reloaded from the exchange's list after every close.

Which sector and industry is Cipla in?

Cipla is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.